
ISRG
Intuitive Surgical Inc
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
520.963
Open
520.210
VWAP
516.86
Vol
1.90M
Mkt Cap
185.88B
Low
513.270
Amount
984.16M
EV/EBITDA(TTM)
60.41
Total Shares
354.71M
EV
181.34B
EV/OCF(TTM)
66.40
P/S(TTM)
21.60
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
2.66B
+10.23%
2.152
-2.63%
2.38B
+16.85%
1.959
+6.45%
2.35B
+16.95%
1.933
+8.62%
Estimates Revision
The market is revising Upward the revenue expectations for Intuitive Surgical, Inc. (ISRG) for FY2025, with the revenue forecasts being adjusted by 0.4% over the past three months. During the same period, the stock price has changed by 10.74%.
Revenue Estimates for FY2025
Revise Upward

+0.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward

-2.84%
In Past 3 Month
Stock Price
Go Up

+10.74%
In Past 3 Month
21 Analyst Rating

14.99% Upside
Wall Street analysts forecast ISRG stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ISRG is 596.35 USD with a low forecast of 440.00 USD and a high forecast of 675.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Buy
2 Hold
1 Sell
Strong Buy

14.99% Upside
Current: 518.620

Low
440.00
Averages
596.35
High
675.00

14.99% Upside
Current: 518.620

Low
440.00
Averages
596.35
High
675.00
BTIG
Ryan Zimmerman
Buy
maintain
$542 -> $566
2025-07-14
Reason
BTIG
Ryan Zimmerman
Price Target
$542 -> $566
2025-07-14
maintain
Buy
Reason
BTIG analyst Ryan Zimmerman raised the firm's price target on Intuitive Surgical to $566 from $542 and keeps a Buy rating on the shares as part of a broader research note previewing Q2 results in MedTech. Healthcare was a laggard in Q2 relative to the S&P, and early into Q3, MedTech is underperforming as fears of Medicaid cuts and hospital closures weigh on the sector following recent legislation, the analyst tells investors in a research note. The fears are likely overblown, though the earnings season is likely to offer a mixed picture as sentiment is extremely binary right now, with some companies pushing extreme valuations and others "left for dead", BTIG notes. The firm adds however that on one hand, inflation is calm, markets are at highs, and Fx has turned demonstrably favorable.
Leerink
NULL
to
Outperform
maintain
$539 -> $587
2025-07-14
Reason
Leerink
Price Target
$539 -> $587
2025-07-14
maintain
NULL
to
Outperform
Reason
Leerink raised the firm's price target on Intuitive Surgical to $587 from $539 and keeps an Outperform rating on the shares ahead of quarterly results. The firm is updating estimates to reflect financial statement disclosures and its updated views, and price targets of several names in the space to reflect recent changes in valuation premiums.
BofA
Travis Steed
Buy
maintain
$650
2025-06-10
Reason
BofA
Travis Steed
Price Target
$650
2025-06-10
maintain
Buy
Reason
Deutsche Bank
Imron Zafar
Hold -> Sell
downgrade
$515 -> $440
2025-06-09
Reason
Deutsche Bank
Imron Zafar
Price Target
$515 -> $440
2025-06-09
downgrade
Hold -> Sell
Reason
Deutsche Bank analyst Imron Zafar downgraded Intuitive Surgical to Sell from Hold with a price target of $440, down from $515.
Deutsche Bank
Hold -> Sell
downgrade
$515 -> $440
2025-06-09
Reason
Deutsche Bank
Price Target
$515 -> $440
2025-06-09
downgrade
Hold -> Sell
Reason
Deutsche Bank downgraded Intuitive Surgical to Sell from Hold with a price target of $440, down from $515. Encroachment to Intuitive's Instruments and Accessories segment by remanufactured instruments is inevitable and likely to be increasingly meaningful over the next few years, the analyst tells investors in a research note. The firm expects a growing number of Intuitive's customers to explore adoption of remanufactured instruments given the potentially significant profitability gains, citing its discussions with multiple robotic surgery programs. Deutsche believes 46% of Intuitive's U.S. I&A revenues could be at risk of encroachment by third party-remanufactured devices. Its model assumes no material impact in 2026 but steadily increasing headwinds in 2027 and especially 2028. Intuitive Surgical shares are down 3% to $538.00 in premarket trading.
Barclays
Overweight
maintain
$635
2025-06-09
Reason
Barclays
Price Target
$635
2025-06-09
maintain
Overweight
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Intuitive Surgical Inc (ISRG.O) is 64.42, compared to its 5-year average forward P/E of 57.64. For a more detailed relative valuation and DCF analysis to assess Intuitive Surgical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair
5Y Average PE
57.64
Current PE
64.42
Overvalued PE
67.23
Undervalued PE
48.05
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair
5Y Average EV/EBITDA
39.31
Current EV/EBITDA
44.40
Overvalued EV/EBITDA
46.95
Undervalued EV/EBITDA
31.68
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair
5Y Average PS
16.57
Current PS
18.64
Overvalued PS
19.62
Undervalued PS
13.51
Financials
Annual
Quarterly
FY2025Q1
YoY :
+19.19%
2.25B
Total Revenue
FY2025Q1
YoY :
+24.22%
583.70M
Operating Profit
FY2025Q1
YoY :
+28.55%
703.70M
Net Income after Tax
FY2025Q1
YoY :
+27.15%
1.92
EPS - Diluted
FY2025Q1
YoY :
+1878.72%
465.00M
Free Cash Flow
FY2025Q1
YoY :
-1.79%
64.69
Gross Profit Margin - %
FY2025Q1
YoY :
+146.07%
20.03
FCF Margin - %
FY2025Q1
YoY :
+7.88%
31.23
Net Margin - %
FY2025Q1
YoY :
+0.96%
15.84
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.4M
USD
12
3-6
Months
36.3M
USD
23
6-9
Months
19.7M
USD
12
0-12
Months
38.0M
USD
20
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 121.09% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
812.5K
Volume
18
6-9
Months
853.5K
Volume
24
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
12
644.5K
Volume
Months
6-9
17
291.5K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.5K
USD
1
3-6
Months
105.0K
USD
7
6-9
Months
56.0K
USD
7
0-12
Months
0.0
USD
0
Bought
0-3
1
32.5K
USD
Months
3-6
2
16.0K
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
2.4M
USD
12
3-6
Months
36.3M
USD
23
6-9
Months
19.7M
USD
12
0-12
Months
38.0M
USD
20
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ISRG News & Events
Events Timeline
2025-07-16 (ET)
2025-07-16
09:20:03
Intuitive Surgical demonstrates telesurgery capabilities

2025-07-10 (ET)
2025-07-10
09:17:44
Intuitive Surgical receives FDA clearance for Vessel Sealer Curved

2025-07-02 (ET)
2025-07-02
09:48:27
Intuitive Surgical's da Vinci 5 Surgical System receives CE Mark

Sign Up For More Events
Sign Up For More Events
News
3.0
07-18CNBCMagnificent Seven earnings kick off next week with stocks near all-time highs
3.0
07-18CNBCThese stocks reporting earnings next have a history of beating expectations
3.0
07-16NASDAQ.COMISRG Factor-Based Stock Analysis - Benjamin Graham
Sign Up For More News
People Also Watch

ABT
Abbott Laboratories
123.670
USD
+2.62%

QCOM
Qualcomm Inc
154.800
USD
+1.44%

VZ
Verizon Communications Inc
40.840
USD
-0.27%

LIN
Linde PLC
465.010
USD
+0.81%

RY
Royal Bank of Canada
132.810
USD
-0.16%

CAT
Caterpillar Inc
413.710
USD
-1.04%

SHEL
Shell PLC
70.280
USD
-0.09%

TXN
Texas Instruments Inc
216.620
USD
+0.01%

GE
General Electric Co
263.270
USD
+1.15%

NVS
Novartis AG
114.250
USD
-0.24%
FAQ

What is Intuitive Surgical Inc (ISRG) stock price today?
The current price of ISRG is 518.62 USD — it has increased 0.48 % in the last trading day.

What is Intuitive Surgical Inc (ISRG)'s business?

What is the price predicton of ISRG Stock?

What is Intuitive Surgical Inc (ISRG)'s revenue for the last quarter?

What is Intuitive Surgical Inc (ISRG)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Intuitive Surgical Inc (ISRG)'s fundamentals?

How many employees does Intuitive Surgical Inc (ISRG). have?
